Q1 2026 · 13F-HR
Caligan Partners LPholdings as filed
Filed 2026-05-15 · accession 0001420506-26-001039
$1.50B
Reported value
28
Positions
2026-03-31
Period end
The Brief · Caligan Partners LP · Q1 2026
AI · grounded in 13F
Caligan Partners LP established a new position in CGON valued at $60.9M. The fund also opened new stakes in SYRE for $44.3M and LBRX for $34.6M. On the sell side, the fund closed its positions in INBX and RAPT, reducing exposure by $37.4M and $21.8M respectively.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 53635D202 | LQDA | LIQUIDIA CORPORATION | $306.4M | 20.4% | 8,118,892 | Common | SOLE |
| 00370M103 | ABVX | ABIVAX SA | $162.8M | 10.8% | 1,461,924 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $160.7M | 10.7% | 1,652,808 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $119.7M | 7.97% | 2,060,719 | Common | SOLE |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $81.0M | 5.39% | 1,393,027 | Common | SOLE |
| 603170101 | MLYS | MINERALYS THERAPEUTICS INC | $75.1M | 5.00% | 2,772,654 | Common | SOLE |
| 30161Q104 | EXEL | EXELIXIS INC | $66.6M | 4.43% | 1,553,262 | Common | SOLE |
| 156944100 | CGON | CG ONCOLOGY INC | $60.9M | 4.05% | 900,000 | CALL | SOLE |
| 87583X109 | TNGX | TANGO THERAPEUTICS INC | $50.4M | 3.35% | 2,408,798 | Common | SOLE |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $48.9M | 3.25% | 1,276,968 | Common | SOLE |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $44.3M | 2.95% | 878,127 | Common | SOLE |
| 000899104 | ADMA | ADMA BIOLOGICS INC | $42.9M | 2.85% | 4,756,511 | Common | SOLE |
| 50180M108 | LBRX | LB PHARMACEUTICALS INC | $34.6M | 2.30% | 1,438,070 | Common | SOLE |
| 929033207 | VOR | VOR BIOPHARMA INC | $34.3M | 2.29% | 1,925,066 | Common | SOLE |
| 78397T202 | SABS | SAB BIOTHERAPEUTICS INC | $30.5M | 2.03% | 7,967,207 | Common | SOLE |
| 67577R102 | IRD | OPUS GENETICS INC | $27.6M | 1.84% | 6,075,028 | Common | SOLE |
| 46124U107 | IVA | INVENTIVA SA | $27.6M | 1.84% | 4,974,906 | Common | SOLE |
| 55287L101 | MBX | MBX BIOSCIENCES INC | $25.3M | 1.69% | 848,590 | Common | SOLE |
| 05338F306 | AVTX | AVALO THERAPEUTICS INC | $24.4M | 1.62% | 1,635,023 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $22.3M | 1.48% | 228,900 | CALL | SOLE |
| 035255108 | ANIK | ANIKA THERAPEUTICS INC | $20.8M | 1.38% | 1,435,130 | Common | SOLE |
| 578784100 | MAZE | MAZE THERAPEUTICS INC | $18.4M | 1.22% | 614,962 | Common | SOLE |
| 92511W207 | VRCA | VERRICA PHARMACEUTICALS INC | $4.9M | 0.33% | 923,910 | Common | SOLE |
| 81728A207 | SNSE | SENSEI BIOTHERAPEUTICS INC | $4.0M | 0.26% | 126,002 | Common | SOLE |
| 00847X104 | AGIO | AGIOS PHARMACEUTICALS INC | $3.0M | 0.20% | 90,000 | CALL | SOLE |
| 000899104 | ADMA | ADMA BIOLOGICS INC | $2.7M | 0.18% | 300,000 | CALL | SOLE |
| 05153U107 | AURA | AURA BIOSCIENCES INC | $1.5M | 0.10% | 229,864 | Common | SOLE |
| 98422T209 | XLO | XILIO THERAPEUTICS INC | $942,996 | 0.06% | 112,128 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.